Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC[C@H](O)C1=CC(O)=C(O)C=C1
InChI
InChIKey=UCTWMZQNUQWSLP-VIFPVBQESA-N
InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1
Molecular Formula | C9H13NO3 |
Molecular Weight | 183.2044 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Epinephrine is a sympathomimetic catecholamine. It acts as a naturally occurring agonist at both alpha and beta-adrenergic receptors. Three pharmacologic types have been identified: alpha 1-, alpha 2-, and beta-adrenergic receptors. Each of these has three subtypes, characterized by both structural and functional differences. The alpha 2 and beta receptors are coupled negatively and positively, respectively, to adenylyl cyclase via Gi or Gs regulatory proteins, and the alpha 1 receptors modulate phospholipase C via the Go protein. Subtype expression is regulated at the level of the gene, the mRNA, and the protein through various transcriptional and postsynthetic mechanisms. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.
Epinephrine increases glycogenolysis, reduces glucose up take by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia and increased blood lactic acid.
Originator
Curator's Comment: Characterized some of the physical and biochemical properties of adrenal extract and laid the platform for purification of the active substance which was first achieved by John Abel in 1899 at Johns Hopkins University, Baltimore and independently by the Japanese scientist Jokichi Takamine in his own laboratory in New York City with the sponsorship of Parke-Davis & Co., and Thomas Aldrich (Parke-Davis & Co., Detroit, Michigan).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331074 |
|||
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9003072 |
33.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ADRENALIN Approved UseAdrenalin® is a non-selective alpha and beta adrenergic agonist indicated for:
Emergency treatment of allergic reactions (Type 1), including anaphylaxis
Induction and maintenance of mydriasis during intraocular surgery |
|||
Preventing | ADRENALIN Approved UseAdrenalin® is a non-selective alpha and beta adrenergic agonist indicated for:
Emergency treatment of allergic reactions (Type 1), including anaphylaxis
Induction and maintenance of mydriasis during intraocular surgery |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
309 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26994624 |
0.3 mg single, intramuscular dose: 0.3 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
EPINEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
386 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26994624 |
5 mg multiple, nasal dose: 5 mg route of administration: Nasal experiment type: MULTIPLE co-administered: |
EPINEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.486 ng/mL |
0.3 mg single, intramuscular dose: 0.3 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
EPINEPHRINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.3 ng × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26994624 |
0.3 mg single, intramuscular dose: 0.3 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
EPINEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
19.4 ng × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26994624 |
5 mg multiple, nasal dose: 5 mg route of administration: Nasal experiment type: MULTIPLE co-administered: |
EPINEPHRINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.724 ng × h/mL |
0.3 mg single, intramuscular dose: 0.3 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
EPINEPHRINE unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.3 mg 1 times / day single, intramuscular Recommended Dose: 0.3 mg, 1 times / day Route: intramuscular Route: single Dose: 0.3 mg, 1 times / day Sources: Page: nda/2012/201739Orig1s000MedR.pdf - p.55 |
healthy, 18 to 45 years old n = 66 Health Status: healthy Age Group: 18 to 45 years old Sex: M+F Population Size: 66 Sources: Page: nda/2012/201739Orig1s000MedR.pdf - p.55 |
Disc. AE: Ventricular extrasystoles... AEs leading to discontinuation/dose reduction: Ventricular extrasystoles (grade 1, 1.5%) Sources: Page: nda/2012/201739Orig1s000MedR.pdf - p.55 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ventricular extrasystoles | grade 1, 1.5% Disc. AE |
0.3 mg 1 times / day single, intramuscular Recommended Dose: 0.3 mg, 1 times / day Route: intramuscular Route: single Dose: 0.3 mg, 1 times / day Sources: Page: nda/2012/201739Orig1s000MedR.pdf - p.55 |
healthy, 18 to 45 years old n = 66 Health Status: healthy Age Group: 18 to 45 years old Sex: M+F Population Size: 66 Sources: Page: nda/2012/201739Orig1s000MedR.pdf - p.55 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19356039/ Page: 2.0 |
yes [Ki 156 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19356039/ Page: 2.0 |
yes [Ki 42.3 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19356039/ Page: 2.0 |
yes [Ki 707 uM] | |||
Page: 8.0 |
yes | |||
Page: 8.0 |
yes | |||
Page: 8.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of succinylcholine and d-tubocurarine on epinephrine-induced arrhythmias during halothane anesthesia in dogs. | 1975 Jan |
|
[Experimental anti-arrhythmic effects of a new beta-adrenergic receptor blocking agent, dl-l-(tert. butylamino)-3-[(2-propinyloxy)phenoxy]2-propanol hydrochloride (dl Kö 1400-Cl)]. | 1976 Jul |
|
Low catecholamine concentrations protect adult rat ventricular myocytes against apoptosis through cAMP-dependent extracellular signal-regulated kinase activation. | 2000 Dec |
|
Effects of ubiquinone-10 on energy metabolism and lipid peroxidation in rats with myocardial ischemia. | 2000 Jul |
|
Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. | 2000 Nov |
|
Influence of antioxidants on blood-brain barrier permeability during adrenaline-induced hypertension. | 2000 Nov |
|
Circulatory support of the sick preterm infant. | 2001 Feb |
|
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. | 2001 Feb |
|
Partial agonist clonidine mediates alpha(2)-AR subtypes specific regulation of cAMP accumulation in adenylyl cyclase II transfected DDT1-MF2 cells. | 2001 Feb |
|
The effects of epidural block on the distribution of lymphocyte subsets and natural-killer cell activity in patients with and without pain. | 2001 Feb |
|
Plasma melatonin concentration before and during testosterone replacement in Klinefelter's syndrome: relation to hepatic indolamine metabolism and sympathoadrenal activity. | 2001 Feb |
|
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. | 2001 Feb |
|
Oral glucose augments the counterregulatory hormone response during insulin-induced hypoglycemia in humans. | 2001 Feb |
|
Troglitazone amplifies counterregulatory responses to hypoglycemia in nondiabetic subjects. | 2001 Feb |
|
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. | 2001 Feb 1 |
|
Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. | 2001 Feb 15 |
|
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. | 2001 Feb 6 |
|
Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. | 2001 Jan |
|
Alterations in myocardial creatinine kinase (CK) and lactate dehydrogenase (LDH) isoenzyme-distribution in a model of left ventricular dysfunction. | 2001 Jan |
|
Influence of ABO blood groups on primary hemostasis. | 2001 Jan |
|
Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells. | 2001 Jan |
|
Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. | 2001 Jan |
|
Guanabenz, an antihypertensive centrally acting alpha2-agonist, suppresses morning elevations in aggregation of human platelets. | 2001 Jan |
|
Regulation of endothelin-1 production in cultured rat vascular smooth muscle cells. | 2001 Jan |
|
Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. | 2001 Jan |
|
The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. | 2001 Jan |
|
Reversal of Haemorrhagic Shock in Rats by Tetrahydroaminoacridine. | 2001 Jan |
|
Hormonal responses to exercise in chronic fatigue syndrome. | 2001 Jan |
|
Genitourinary injuries in the newborn. | 2001 Jan |
|
Fatalities due to anaphylactic reactions to foods. | 2001 Jan |
|
Viral croup. | 2001 Jan |
|
Effects of high extracellular [K+] and adrenaline on force development, relaxation and membrane potential in cardiac muscle from freshwater turtle and rainbow trout. | 2001 Jan |
|
Effects of human pregnancy on cardiac autonomic function above and below the ventilatory threshold. | 2001 Jan |
|
Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. | 2001 Jan |
|
Hypoxic vasoconstriction of cyclostome systemic vessels: the antecedent of hypoxic pulmonary vasoconstriction? | 2001 Jan |
|
A single bout of exercise induces beta-adrenergic desensitization in human adipose tissue. | 2001 Jan |
|
Chromaffin-adrenocortical cell interactions: effects of chromaffin cell activation in adrenal cell cocultures. | 2001 Jan |
|
Lack of effect of incretin hormones on insulin release from pancreatic islets in the bile duct-ligated rats. | 2001 Jan |
|
Reference intervals for glucose, beta-cell polypeptides, and counterregulatory factors during prolonged fasting. | 2001 Jan |
|
Cardiovascular effects of hypercarbia in rainbow trout (Oncorhynchus mykiss): a role for externally oriented chemoreceptors. | 2001 Jan |
|
Neuroendocrine responses to experimentally-induced psychological stress in healthy humans. | 2001 Jan |
|
Development of glaucoma after phacoemulsification for removal of cataracts in dogs: 22 cases (1987-1997). | 2001 Jan 1 |
|
Synthesis and characterization of an immobilized phenylethanolamine N-methyltransferase liquid chromatographic stationary phase. | 2001 Jan 1 |
|
Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci. | 2001 Jan 15 |
|
Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. | 2001 Jan 15 |
|
Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. | 2001 Jan 30 |
|
The role of nitric oxide in bradycardia of rats with obstructive cholestasis. | 2001 Jan 5 |
|
Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism. | 2001 Jan 5 |
|
Daily cost of ophthalmic solutions for treating glaucoma in Japan. | 2001 Jan-Feb |
|
Effect of amlodipine on cardiopulmonary performance in volunteers. | 2001 Jan-Feb |
Patents
Sample Use Guides
Anaphylaxis:
o Adults and Children 30 kg (66 lbs) or more: 0.3 to 0.5 mg (0.3 to 0.5 mL) intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary
o Children 30 kg (66 lbs) or less: 0.01 mg/kg (0.01 mL/kg), up to 0.3 mg (0.3 mL), intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary (2.1)
Intraocular surgery: Dilute 1 mL with 100 to 1000 mL of an ophthalmic irrigation fluid, for ophthalmic irrigation or intracameral injection
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28603032
Treatment of primary human hepatocytes with 10μM epinephrine for 24h repressed mRNA expression of various transporters, such as the sinusoidal influx transporters NTCP, OATP1B1, OATP2B1, OAT2, OAT7 and OCT1 and the efflux transporters MRP2, MRP3 and BSEP, whereas it induced that of MDR1, but failed to alter that of BCRP.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:12:07 GMT 2023
by
admin
on
Fri Dec 15 15:12:07 GMT 2023
|
Record UNII |
YKH834O4BH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
1.2 (LID/EPI)
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
NDF-RT |
N0000175552
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
21.5
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-VATC |
QB02BC09
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
13735-6
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
33874-9
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
C01CA24
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
CFR |
21 CFR 346.12
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
WHO-ATC |
S01EA01
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
WHO-VATC |
QS01EA01
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
14711-6
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
2230-1
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
NDF-RT |
N0000175570
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
2232-7
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-VATC |
QC01CA24
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
B02BC09
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
WHO-VATC |
QR03AK01
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
134800
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
03
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
13734-9
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
16111-7
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
25.1
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
NDF-RT |
N0000175555
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
CFR |
21 CFR 341.16
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
LOINC |
24521-7
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.2
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
2231-9
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
44837-3
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
NDF-RT |
N0000000209
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
25908-5
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
R03AK01
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
LOINC |
11046-0
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
NDF-RT |
N0000000245
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-VATC |
QR03AA01
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
R01AA14
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
WHO-VATC |
QR01AA14
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-VATC |
QA01AD01
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
14712-4
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
S01EA51
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
NDF-RT |
N0000007715
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
49552-3
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
A01AD01
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
FDA ORPHAN DRUG |
133200
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
LOINC |
24522-5
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
25909-3
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
LOINC |
32015-0
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
WHO-ATC |
R03AA01
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
||
|
LOINC |
43248-4
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
||
|
NCI_THESAURUS |
C88516
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
51028-73-0
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
SUPERSEDED | |||
|
EPINEPHRINE
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
1236970
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
DTXSID5022986
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
DB00668
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
SUB06568MIG
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
CHEMBL679
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
3992
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
D004837
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
1028
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
SUB130356
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
ALTERNATIVE | |||
|
C473
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
28918
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
Epinephrine (medication)
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
4289
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
100000092380
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
479
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
YKH834O4BH
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
m4944
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
200-098-7
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
Epinephrine
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
5816
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
EPINEPHRINE
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | Other name: Adrenaline. (In certain countries the name Adrenaline is a trademark. In those countries this name may be used onlywhen applied to the product issued by the owners of the trademark.)Description: A white or almost white, microcrystalline powder; odourless.Solubility: Very slightly soluble in water; practically insoluble in ethanol (~750 g/l) TS, ether R and acetone R.Category: Sympathomimetic.Storage: Epinephrine should be kept in a hermetically closed container, protected from light.Additional information: Epinephrine gradually darkens in colour on exposure to air and light. Even in the absence of light,Epinephrine is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.RequirementsDefinition: Epinephrine contains not less than 98.5% and not more than 101.0% of C9H13NO3, calculated with reference to thedried substance. | ||
|
2142
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
51-43-4
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY | |||
|
62786
Created by
admin on Fri Dec 15 15:12:08 GMT 2023 , Edited by admin on Fri Dec 15 15:12:08 GMT 2023
|
PRIMARY | |||
|
YKH834O4BH
Created by
admin on Fri Dec 15 15:12:07 GMT 2023 , Edited by admin on Fri Dec 15 15:12:07 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
Assay in chinese hamster ovary (CHO) cells stably expressing the three β-adrenergic receptor subtypes at comparable leve50 to 80 pM 125I-CYP were used as radioligand. Experiments were done in the presence of 100 µM GTP.
Ki
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
RACEMATE -> ENANTIOMER |
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
WEAK AGONIST->TARGET |
Assay in chinese hamster ovary (CHO) cells stably expressing the three β-adrenergic receptor subtypes at comparable leve50 to 80 pM 125I-CYP were used as radioligand. Experiments were done in the presence of 100 µM GTP.
Ki
|
||
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
Assay in chinese hamster ovary (CHO) cells stably expressing the three β-adrenergic receptor subtypes at comparable leve50 to 80 pM 125I-CYP were used as radioligand. Experiments were done in the presence of 100 µM GTP.
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
Unit: percent of tritium in the urine;
See table 1 the source.
IN-VIVO
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
Unit: percent of tritium in the urine;
See table 1 in the source document.
IN-VIVO
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
Unit: percent of tritium in the urine;
See table 1 in the source document.
IN-VIVO
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
Unit: percent of tritium in the urine;
See table 1 in the source document.
IN-VIVO
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurities by the corresponding correction factor: impurity D = 0.7; impurity E = 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of content, multiply the peak areas of the following impurities by the corresponding correction factor: impurity D = 0.7; impurity E = 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|